Moreover, the 36-month beta value for DSGN is 1.93. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for DSGN is 32.10M and currently, short sellers hold a 8.07% of that float. On November 14, 2024, DSGN’s average trading volume was 238.81K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DSGN) stock’s latest price update
The stock of Design Therapeutics Inc (NASDAQ: DSGN) has increased by 8.54 when compared to last closing price of 6.91.Despite this, the company has seen a gain of 26.26% in its stock price over the last five trading days. globenewswire.com reported 2024-11-13 that CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:
DSGN’s Market Performance
DSGN’s stock has risen by 26.26% in the past week, with a monthly rise of 39.15% and a quarterly rise of 74.83%. The volatility ratio for the week is 11.55% while the volatility levels for the last 30 days are 7.94% for Design Therapeutics Inc The simple moving average for the past 20 days is 29.60% for DSGN’s stock, with a 79.41% simple moving average for the past 200 days.
Analysts’ Opinion of DSGN
Many brokerage firms have already submitted their reports for DSGN stocks, with Piper Sandler repeating the rating for DSGN by listing it as a “Overweight.” The predicted price for DSGN in the upcoming period, according to Piper Sandler is $12 based on the research report published on May 07, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see DSGN reach a price target of $6, previously predicting the price at $42. The rating they have provided for DSGN stocks is “Neutral” according to the report published on November 14th, 2023.
Wedbush gave a rating of “Neutral” to DSGN, setting the target price at $6 in the report published on August 15th of the previous year.
DSGN Trading at 37.33% from the 50-Day Moving Average
After a stumble in the market that brought DSGN to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 7.91% of gains for the given period.
Volatility was left at 7.94%, however, over the last 30 days, the volatility rate increased by 11.55%, as shares surge +32.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +55.93% upper at present.
During the last 5 trading sessions, DSGN rose by +26.26%, which changed the moving average for the period of 200-days by +217.80% in comparison to the 20-day moving average, which settled at $5.79. In addition, Design Therapeutics Inc saw 183.02% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DSGN starting from William Arsani, who sale 814,874 shares at the price of $4.25 back on Aug 09 ’24. After this action, William Arsani now owns 0 shares of Design Therapeutics Inc, valued at $3,463,214 using the latest closing price.
Logos SPV 1 LP, the Director of Design Therapeutics Inc, proposed sale 814,874 shares at $4.24 during a trade that took place back on Aug 09 ’24, which means that Logos SPV 1 LP is holding shares at $3,455,066 based on the most recent closing price.
Stock Fundamentals for DSGN
Current profitability levels for the company are sitting at:
- -72.57 for the present operating margin
- 0.48 for the gross margin
The net margin for Design Therapeutics Inc stands at -57.02. The total capital return value is set at -0.24. Equity return is now at value -17.78, with -17.02 for asset returns.
Based on Design Therapeutics Inc (DSGN), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -26.4. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -471.4.
Currently, EBITDA for the company is -66.33 million with net debt to EBITDA at 0.47. When we switch over and look at the enterprise to sales, we see a ratio of 472.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 34.61.
Conclusion
To wrap up, the performance of Design Therapeutics Inc (DSGN) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
